Every Form 4 that Amgen Inc (AMGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AMGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMGN filings page.
Amgen Inc. executive Gordon Murdo reported routine tax-related share dispositions, not open-market sales. On May 2, 2026, he had 1,593 shares of common stock withheld at $329.82 per share to cover tax obligations. Following these transactions, he directly holds 48,699 Amgen shares.
A footnote explains his holdings include 488 Dividend Equivalents tied to unvested Restricted Stock Units under Amgen’s equity incentive plan, which pay out in shares according to the vesting schedule.
Amgen Inc. vice president, finance and chief accounting officer Matthew C. Busch reported routine share dispositions related to tax withholding. On May 2, 2026, a total of 68 shares of common stock were withheld at $329.82 per share to satisfy tax obligations tied to equity awards.
Following these transactions, Busch directly holds 3,980 shares of Amgen common stock. A footnote explains that his holdings include 49 Dividend Equivalents linked to unvested Restricted Stock Units, which will be settled in common shares as those units vest.
AMGEN INC Chairman, CEO and President Robert A. Bradway reported routine equity-related activity in company stock. The filing shows tax-withholding dispositions totaling 5,057 shares of common stock at $329.82 per share, used to cover exercise price or tax liabilities tied to equity awards.
Bradway also reports indirect holdings in Amgen common stock through his spouse and related GRATs, alongside Dividend Equivalents credited to unvested Restricted Stock Units that pay out in shares as they vest. These transactions do not reflect open-market buying or selling decisions.
Amgen Inc. executive Esteban Santos, EVP of Operations, reported an automatic share disposition tied to taxes rather than an open-market trade. On March 16, 2026, 5,621 shares of common stock were transferred at $366.21 per share to satisfy a tax liability by delivering securities.
After this transaction, Santos directly holds 82,404 common shares, which include 696 Dividend Equivalents that will pay out in shares as restricted stock units vest. He also has an additional indirect holding of 909.9928 shares through Amgen's 401(k) Plan stock fund.
AMGEN INC executive David M. Reese reported a compensation-related share disposition tied to tax obligations. On March 16, 2026, 6,022 shares of Amgen common stock were delivered at $366.21 per share to satisfy tax liability or exercise costs, a transaction coded as tax-withholding. Following this event, Reese directly held 41,787 Amgen shares. A portion of his position also reflects dividend equivalents credited to unvested restricted stock units that will be paid in shares as they vest.
Amgen Inc. senior vice president Derek Miller reported a routine tax-withholding transaction in company stock. On March 16, 2026, 1,616 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations related to equity compensation. Following this withholding, Miller directly holds 12,173 shares, which include 197 dividend equivalents tied to unvested restricted stock units that will pay out in shares as they vest.
Amgen Inc. senior vice president of business development Rachna Khosla reported a tax-related share disposition on company stock. On March 16, 2026, 707 shares of Amgen common stock were withheld at a price of $366.21 per share to satisfy tax obligations, rather than sold in the open market.
After this tax-withholding disposition, Khosla directly holds 8,291 Amgen shares. This amount includes 120 Dividend Equivalents granted under Amgen’s 2009 equity incentive plan, which convert into common stock on a one-to-one basis as related restricted stock units vest.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel reported a routine tax-related share withholding. On March 16, 2026, 787 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations tied to equity compensation.
After this tax-withholding disposition, she directly holds 8,488 Amgen shares, which include 122 dividend equivalents that will pay out in shares as they vest. She also indirectly holds 106.1873 shares through the company’s 401(k) plan stock fund.
Amgen Inc. EVP & CFO Peter H. Griffith reported a Form 4 transaction showing a tax-related share disposition. On March 16, 2026, 5,748 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations by delivering shares. After this withholding transaction, he directly holds 49,001 shares of common stock. His holdings include 756 Dividend Equivalents granted under Amgen’s equity incentive plan, which are paid out in shares on a one-for-one basis as related restricted stock units vest.
Amgen Inc. executive Jonathan P. Graham reported a routine tax-related share disposition. On this Form 4, 5,353 shares of Amgen common stock were withheld at $366.21 per share to satisfy tax obligations, rather than sold in the open market. After this withholding, he directly owns 39,267 shares. The reported holdings include 659 dividend equivalent units that will pay out in Amgen shares as related restricted stock units vest.
Amgen Inc. executive Murdo Gordon reported a routine tax-related share disposition. On March 16, 2026, the EVP, Global Commercial Operations delivered 6,691 shares of Amgen common stock at $366.21 per share to cover tax obligations, rather than selling them on the open market.
Following this tax-withholding disposition, Gordon directly holds 50,292 Amgen shares. His holdings also include 825 dividend equivalent units tied to unvested restricted stock units, which will be paid out in Amgen common stock as those awards vest.
Amgen Inc.’s Chairman, CEO and President Robert A. Bradway reported a tax-related share disposition. On March 16, 2026, 21,294 shares of Amgen common stock were withheld at $366.21 per share to cover tax obligations, a non-market transaction classified as a tax-withholding disposition. Following this, Bradway directly holds 501,862 shares of common stock. He also reports indirect holdings of 60,060 shares by a GRAT, 60,060 shares by a spousal GRAT, and 29,940 shares by his spouse. The direct holdings include 2,696 dividend equivalents that will settle in shares as related restricted stock units vest.
Amgen Inc. vice president, finance and chief accounting officer Matthew C. Busch reported a small tax-related share disposition. On the reported date, 327 shares of Amgen common stock were withheld at a price of $366.21 per share to satisfy tax obligations, classified as a tax-withholding disposition rather than an open-market sale.
After this transaction, Busch directly held 4,048 shares of Amgen common stock. His holdings include 68 dividend equivalents credited under Amgen’s equity incentive plan, which will be paid out in common shares as related restricted stock units vest.
Amgen Inc. Chairman, CEO and President Robert A. Bradway reported several equity transactions in the company’s stock. He exercised stock options, receiving 119,782 shares of common stock at $156.35 per share through a derivative exercise.
To cover the option exercise price and related tax withholding, 84,285 shares of common stock were withheld by the company and disposed of under a tax-withholding arrangement. After these transactions, Bradway directly owned 492,643 shares of Amgen common stock, and also had indirect ownership of 90,000 shares held through a GRAT and a spousal GRAT.
The directly owned shares include 2,414 dividend equivalents tied to unvested restricted stock units, which will be paid in Amgen common stock on a one-to-one basis as those units vest.
Santos Esteban reported acquisition or exercise transactions in this Form 4 filing.
Amgen executive Esteban Santos reported an equity award of 11,259 shares of common stock granted on 2026-03-03. The grant was recorded at a stated price of $0.00 per share as a stock award, bringing his directly held Amgen shares to 87,877.
The direct holdings figure includes 624 Dividend Equivalents credited under Amgen’s 2009 Equity Incentive Plan, which pay out in common stock as related RSUs vest, with cash paid for any remaining fractional share amount. Separately, Santos has indirect holdings representing 903.8036 shares through the company’s 401(k) plan stock fund.
REESE DAVID M reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. executive David M. Reese, EVP & Chief Technology Officer, reported an equity award of 12,063 shares of common stock on March 3, 2026. The award was recorded at $0.00 per share, reflecting a grant rather than an open‑market purchase.
After this grant, Reese directly owned 47,650 Amgen common shares. This total includes 667 Dividend Equivalents (DEs) credited under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which pay out in shares according to the vesting schedule.
Amgen Inc. senior vice president of human resources Derek Miller reported an award of 3,484 shares of Amgen common stock on March 3, 2026. The shares were acquired at a stated price of $0.00 per share as a grant or similar equity award, bringing his directly held common stock to 13,744 shares after the transaction.
The reported holdings include 176 dividend equivalents granted under Amgen’s equity incentive plan, which are credited to Miller’s unvested restricted stock units and paid out in common shares on a one‑to‑one basis as those units vest.
Amgen Inc. senior vice president of business development Rachna Khosla received an equity award of 1,876 shares of common stock on March 3, 2026, reported as a grant, award, or other acquisition with no purchase price. After this award, her directly held common stock position increased to 8,972 shares.
This total includes 107 dividend equivalents credited under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan. These dividend equivalents are tied to unvested restricted stock units and will be paid out in Amgen common shares on a one-to-one basis as the underlying awards vest, with cash paid for any remaining fractional share amounts.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel received an equity award of 2,010 shares of Amgen common stock on March 3, 2026. The award is recorded at a price of $0.00 per share, reflecting a grant rather than an open-market purchase.
After this grant, she directly holds 9,249 Amgen shares. A footnote states this total includes 110 dividend equivalents credited under Amgen’s equity incentive plan, which convert to common shares as related restricted stock units vest. She also indirectly holds 105.465 Amgen shares through the company’s 401(k) plan stock fund.
Amgen Inc. executive vice president and CFO Peter H. Griffith reported an equity award of 12,063 shares of common stock on a Form 4. The shares were acquired as a grant at no cash cost, increasing his directly held stake to 54,587 shares.
The reported holdings include 676 dividend equivalent units granted under Amgen’s 2009 Equity Incentive Plan. These dividend equivalents are credited to his unvested restricted stock units and will be paid out in Amgen common shares on a one-for-one basis as the underlying awards vest, with cash paid for any remaining fractional share amounts.
Amgen Inc. reported that executive vice president, general counsel and secretary Jonathan P. Graham acquired 10,723 shares of Amgen common stock on March 3, 2026 through a grant or award, at a stated price of $0.0000 per share.
After this award, Graham directly holds 44,478 shares of Amgen common stock. The total includes 590 dividend equivalents credited under Amgen’s equity incentive plan, which will pay out in shares on a one-to-one basis as the related restricted stock units vest.
Gordon Murdo reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. executive vice president of Global Commercial Operations Murdo Gordon received a grant of 13,403 shares of Amgen common stock as an equity award, with no cash paid per share. After this grant, he directly holds 56,807 shares. The total includes 740 dividend equivalents credited to his unvested restricted stock units, which will be paid in shares on a one-to-one basis according to their vesting schedule.
Bradway Robert A reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc.'s Chairman, CEO and President Robert A. Bradway reported an equity award of 42,657 shares of common stock on March 3, 2026. The shares were granted at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
Following this grant, his direct ownership increased to 457,146 common shares, which include 2,414 dividend equivalents credited to unvested RSUs under Amgen’s equity incentive plan. The filing also shows indirect holdings of 90,000 shares held by a GRAT and 90,000 shares held by a spousal GRAT.
Amgen Inc. reported that VP, Finance & CAO Matthew C. Busch acquired 938 shares of common stock on March 3, 2026 through a grant or award, at a stated price of $0.00 per share. After this equity award, his directly held common stock position increased to 4,361 shares.
The reported holdings include 60 dividend equivalents (DEs) granted under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan. These DEs are credited to Busch’s unvested restricted stock units and will be paid out in Amgen common shares on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Amgen EVP of Operations Esteban Santos exercised stock options and sold shares. On February 26, 2026, he exercised nonqualified stock options for 30,501 and 24,291 shares of Amgen common stock at exercise prices of $162.6000 and $177.4600 per share, respectively, and received common stock through derivative exercises.
On the same date, he sold 30,501 and 24,291 shares of common stock in open-market transactions at an average price of $379.1173 per share, for total sales of 54,792 shares, including shares sold to cover the option exercise price and required withholding taxes. After these transactions, he directly owned 76,618 shares and held an additional 903.8036 shares indirectly through the company’s 401(k) plan.
Amgen Inc. vice president sells a small block of shares. Matthew C. Busch, Amgen's VP, Finance & CAO, reported an open-market sale of 1,000 shares of Amgen common stock at a price of $375.79 per share. After this transaction, he directly holds 3,423 shares of Amgen common stock.
The filing notes that these holdings include 60 dividend equivalents granted under Amgen's equity incentive plan. These dividend equivalents are tied to unvested restricted stock units and will be paid out in Amgen shares on a one-to-one basis as those awards vest.
Amgen Inc. executive James E. Bradner, EVP, Research and Development, reported two dispositions of Amgen common stock in transactions coded F on February 9, 2026. The Form 4 shows 2,151 shares and 953 shares disposed of at $384.32 per share in separate entries.
After these transactions, the reported directly owned balances were 28,331 shares and 27,378 shares in the respective lines. The holdings include 1,205 dividend equivalents granted under Amgen’s 2009 Equity Incentive Plan, which are paid out in shares on a one-to-one basis as related RSUs vest.
Amgen Inc. (AMGN) senior vice president and chief compliance officer Nancy A. Grygiel reported option exercises and related stock sales. On 11/20/2025, she exercised options to buy 1,500 shares of common stock at $177.46 per share and 1,639 shares at $162.60 per share, then sold 1,500 shares and 1,639 shares of common stock at an average price of $337.2625 per share.
After these transactions, she directly beneficially owned 7,225 shares of Amgen common stock, which include 96 dividend equivalent units tied to unvested RSUs, and also held 104.6847 shares through the company 401(k) plan’s stock fund. She continued to hold 1,970 nonqualified stock options from the 04/27/2020 grant, while the 05/01/2019 option grant was fully exercised.
Amgen (AMGN) insider transaction: The company’s SVP of Business Development reported a sale of 890 shares of Amgen common stock on 11/12/2025 (Transaction Code S) at an average price of $336.2422. The filing notes trade prices ranged from $336.2219 to $336.30 per share. Following the transaction, the reporting person beneficially owns 7,082 shares, held directly. This balance includes 93 Dividend Equivalents credited to unvested RSUs under Amgen’s equity plan.
Amgen (AMGN) insider transaction: EVP, Global Commercial Ops Murdo Gordon filed a Form 4 reporting an open‑market sale of 6,879 shares of common stock on 11/12/2025 at an average price of $336.8326.
After the trade, Gordon beneficially owns 41,923 shares. This figure includes 647 dividend equivalents (DEs) credited to unvested RSUs under Amgen’s equity plan, which pay out in shares on a one‑to‑one basis according to the vesting schedule.
Amgen (AMGN) reported insider activity by its EVP & Chief Technology Officer. On 11/11/2025, the officer made a gift of 6,490 shares of common stock, followed by a gift of 309 shares on 11/12/2025, both at $0 per share (Form 4 code G). After these transactions, the officer beneficially owned 35,503 shares.
The filing notes the first gift went to a charitable donor‑advised fund and the second to a non‑profit organization. The reported holdings include 583 dividend equivalents credited to unvested RSUs, payable in shares pursuant to the vesting schedule.
Amgen Inc. (AMGN) reported an insider transaction. Director S. Omar Ishrak acquired 218.6134 shares of Common Stock on 11/07/2025 at $0, increasing his beneficial ownership to 6,507.5436 shares, held directly.
The filing notes these holdings include 338 Dividend Equivalents credited under the Director Program, which are paid in Amgen Common Stock on a one-to-one basis, with cash for any remaining fractional share amount.
Amgen (AMGN) director Charles M. Holley reported acquiring 265.4591 shares of common stock on 11/07/2025 at a stated price of $0. Following the transaction, he beneficially owns 11,834.085 shares directly and 1,260 shares indirectly through the Holley Family Trust. The holdings include 1,393 Dividend Equivalents credited on vested but deferred RSUs, which are paid out in shares on a one-to-one basis.
Amgen (AMGN) reported a director transaction. On 11/07/2025, the reporting person acquired 218.6134 shares of common stock at $0, reflecting equity credited under the company’s director program.
Following this activity, the director beneficially owned 4,958.6425 shares, held directly. The filing notes these shares include 268 Dividend Equivalents credited on vested but deferred RSUs, which are paid out in shares on a one-to-one basis with cash for any remaining fractional amount.
Amgen Inc. insider filing shows that SVP, Business Development Rachna Khosla reported a transaction dated 11/05/2025. The filing lists a Code F disposition of 226 shares of common stock at $296.7 per share, resulting in 7,972 shares beneficially owned directly. The reported share balance includes 93 Dividend Equivalents tied to unvested RSUs under Amgen’s 2009 Equity Incentive Plan, which are credited and paid in shares on a one-to-one basis according to the vesting schedule.
Amgen (AMGN) officer Matthew C. Busch, VP, Finance & CAO, reported a Form 4 transaction dated 11/05/2025.
He disposed of 202 shares of common stock at $296.70 per share (Transaction Code F). Following the transaction, he beneficially owns 4,414 shares, held directly.
Footnote: the reported holdings include 51 Dividend Equivalents credited on unvested RSUs, which are paid in shares pursuant to plan terms.